Nello Mainolfi, PhD
Founder, President & Chief Scientific Officer
Before founding Kymera, Nello was head of drug discovery at Raze Therapeutics (an Atlas portfolio company) where he helped develop first in class molecules against novel cancer metabolism targets with implications in both oncology and immuno-metabolism. Nello started his drug discovery career in the global discovery chemistry group at the Novartis Institutes for Biomedical Research, where he contributed and in most cases led teams to the identification of more than 10 compounds that have entered preclinical and clinical development across a series of disease areas. Notably first in class small molecules inhibitors of several complement proteins for inflammation and ocular diseases. While at Novartis he also championed new technologies such as using fragment-based drug discovery as a core strategy to deliver multiple development candidates. Nello has authored >40 papers and patents and has written reviews in the areas of medicinal chemistry and drug discovery. Nello was trained at Imperial College, University of London and The Scripps Research Institute in California.
Bruce Jacobs, CFA, MBA
Chief Financial Officer
As CFO, Bruce directs financial operations and investor relations for Kymera Therapeutics. Bruce joined Kymera with more than 25 years of experience in health care financial services, investment banking and equity research. He previously was Managing Partner for Westfield Capital Management, a Boston-based equity investment firm. In addition to his core portfolio management responsibilities, he served on the firm’s Management Committee and as the Health Care Team Lead. Bruce was also a Director with Alex Brown & Sons/Deutsche Bank and part of the health care investment banking group and the equity research team. He graduated magna cum laude from the Wharton School of the University of Pennsylvania, earned a Master of Business Administration from the Harvard Business School and is a Chartered Financial Analyst. Bruce is currently Chair of the Board of Directors at Boys & Girls Clubs of Boston.
Jared Gollob, MD
Chief Medical Officer
In his role as CMO, Jared leads clinical development for Kymera Therapeutics, advancing clinical candidates identified by Kymera’s proprietary Pegasus™ targeted protein degradation platform. Jared joined Kymera from Alnylam Pharmaceuticals, where he was Vice President of Clinical Development and Global Vice President of Medical Affairs for Amyloidosis. There, he led early and late stage clinical programs in infectious disease, oncology, and amyloidosis that provided the first proof of concept in humans for RNA interference therapeutics and culminated in the FDA and EMA approvals of ONPATTROTM for the treatment of hereditary transthyretin amyloidosis. Jared previously held academic positions at Harvard Medical School and Duke University School of Medicine, and was on staff at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Duke University Medical Center, where he was engaged in both clinical and laboratory research in oncology and immunology. He has authored more than 50 peer-reviewed papers published in top-tier medical and scientific journals. Jared received his BA and MD from Columbia University, and completed clinical training in internal medicine and medical oncology at Massachusetts General Hospital and the Dana-Farber Cancer Institute, respectively.
Board of Directors
Bruce Booth, DPhil
Bruce Booth is a partner at Atlas Venture where he focuses on novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies. He is currently chairman of AvroBio (NASDAQ:AVRO), Hotspot Therapeutics, Nimbus Therapeutics, Rodin Therapeutics, and Unum Therapeutics (NASDAQ:UMRX), and also serves on the boards of Lysosomal Therapeutics, and Magenta Therapeutics (NASDAQ:MGTA). He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Stromedix (acquired by Biogen), Zafgen (NASDAQ:ZFGN), miRagen Therapeutics (NASDAQ:MGEN), and a number of other ventures.
Bruce serves as an advisor in various capacities to UCB, Takeda, and the Gates Foundation. He also serves on the board of the National Venture Capital Association and of New England Disabled Sports, a charity dedicated to adaptive sports. Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. His work focused on the study of HIV and tumor immune responses. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.
Steve Hall, PhD
Steve is a General Partner at Lilly Ventures and has more than 25 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations. Prior to joining Lilly Ventures, Steve was SVP of R&D at Serenex, Inc., where he was also a co-founder. He also has held operational and leadership roles at Eli Lilly, Sphinx Pharmaceuticals, and Bristol-Myers Squibb in the areas of oncology, cardiovascular disease, and lead generation technologies. Steve currently sits on the boards of Cavio Pharma, Esanex, FORMA Therapeutics, Hydra Biosciences, Lysosomal Therapeutics and Nimbus Therapeutics. Steve is the author of more than 40 papers and 60 patents. He received his B.S. in chemistry from Central Michigan University and his PhD in organic chemistry from Massachusetts Institute of Technology.
Andrew Hedin is an investor in Bessemer’s Cambridge office where he focuses on investments in healthcare. Prior to joining Bessemer in 2015, Andrew worked at F-Prime Capital, Fidelity’s healthcare-focused venture capital fund, where he invested broadly across life sciences and healthcare technology, and he has also spent time with Leerink Partners.
He earned an MBA with honors from The Wharton School, where he majored in health care management and finance, as well as a degree in biological basis of behavior from the University of Pennsylvania.
Wei Li, PhD
Dr. Wei Li has served as a Managing Partner at 6 Dimensions Capital, a healthcare investment group, since October 2017, when it was formed by the merger of WuXi Healthcare Ventures and Frontline BioVentures, each a venture capital firm with a focus on life sciences companies. He served as Founding Partner of WuXi Healthcare Ventures from April 2015 to October 2017. Dr. Li served as an Executive Partner of Fidelity Biosciences and Fidelity Growth Partner Asia, both venture capital firms, from January 2013 to March 2015. Dr. Li previously held roles as an Associate at Baird Venture Partners, a venture capital firm, and as a Scientist at Vertex Pharmaceuticals, a pharmaceutical company, where he worked on drug discovery projects and technology licensing due diligence. Dr. Li currently serves on the boards of directors of a number of privately-held life sciences companies.
Dr. Li holds a B.S. with distinction in chemical physics from the University of Science and Technology of China, a Ph.D. in biochemistry and mammalian genetics from Harvard University and an MBA with a concentration in finance, accounting and marketing from the Kellogg School of Management at Northwestern University.
Joanna Horobin, MB, ChB
Joanna Horobin, M.B., Ch.B, is Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals, Inc. Prior to joining Idera in November 2015, Dr. Horobin was most recently the Chief Medical Officer of Verastem, Inc. and previously served as Chief Executive Officer of Syndax Pharmaceuticals. Additionally, Dr. Horobin held several roles of increasing responsibility at global pharmaceutical corporations such as Rhône-Poulenc Rorer (now Sanofi) where she spearheaded the launch of the global Oncology business unit which included the commercial introduction of Taxotere® (docetaxel) in breast cancer and Campto/Camptosar® (CPT11) for colorectal cancer. Dr. Horobin also led a successful joint venture with Chugai to launch Granocyte® (lenograstim). Prior, Dr. Horobin played significant leadership roles in the approvals of Lovenox®, Celectol®, Augmentin®, Timentin®, temocillin, Bactroban® and Relafen®/Reliflex®.
Dr. Horobin currently serves as a Non-Executive Director of Nordic Nanovector ASA. Dr. Horobin received her medical degree from the University of Manchester, United Kingdom.
Donald W. Nicholson, PhD
Dr. Don Nicholson is the former Chief Executive Officer of Nimbus Therapeutics. He joined from Merck, where he held various strategic, leadership and operational roles in diverse therapeutic areas, including respiratory, inflammation, immunology, bone, endocrine, urology, infectious disease and neurosciences. He began his career in 1998 at the Merck-Frosst Centre for Therapeutic Research in Montreal and advanced through various positions of increasing responsibility including Vice President & Site Head of the Merck Neurosciences Research site in San Diego, and most recently as Vice President and Worldwide Discovery Head for the Respiratory & Immunology Franchise, based in Kenilworth, N.J. Don has co-authored more than 150 publications in peer-reviewed scientific and medical journals and is internationally recognized for his contributions to the field of apoptotic cell death. He received his Ph.D. and an Honors B.Sc. degree in Biochemistry from the University of Western Ontario, and trained as a Medical Research Council postdoctoral fellow at the University of Munich in Germany. He is the recipient of multiple academic and professional honors.
Christopher O’Donnell, PhD
Christopher O’Donnell, PhD is Executive Director, Worldwide Research, Development & Medical and Principal, Pfizer Ventures. Chris has 20 years of scientific leadership at Pfizer and a strong track record of delivering clinical candidates across multiple disease areas and modalities. Prior to Pfizer Ventures, Chris built and led the Applied Synthesis Technologies group within Pfizer WR&D to help accelerate the delivery of Pfizer’s small molecule portfolio. Prior to that, Chris built and led Pfizer’s Antibody Drug Conjugate Oncology Medicinal Chemistry group which delivered new linker, payload and conjugation methods resulting in 7 conjugates entering clinical development. Chris started his career in the Neuroscience Medicinal Chemistry group where he invented and helped deliver numerous clinical candidates, with the most advanced being the AMPA positive allosteric modulator in Phase II that was licensed to Biogen. Chris has co-authored 55 peer reviewed manuscripts and is the inventor/co-inventor on 25 patents.
Chris earned his BS in Chemistry from the University of Illinois-Urbana/Champaign and his PhD in Chemistry from the University of Wisconsin-Madison and joined Pfizer after his post-doctoral research studies as an American Cancer Society Fellow at the University of California – Irvine.
Chris currently sits on the boards of Adapsyn Biosciences and Storm Therapeutics (UK) and is a board observer of BioAtla, Morphic Therapeutic, Petra Therapeutics and Strata Oncology.
Scientific Advisory Board
Professor of Pharmacology, University of Washington and Investigator, Howard Hughes Medical Institute
Professor, Rockefeller University and Investigator, Howard Hughes Medical Institute
Chair, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine and Investigator, Howard Hughes Medical Institute
American Cancer Society Professor and Director of the Center for Lymphoid Malignancies, Columbia University